Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2022 | TIME STUDY

The TIME study, presented by Dr. Thomas MacDonald, is a randomized study of over 21,000 patients with high blood pressure with a follow-up beyond 5 years.

ESC 2022

As is widely known, high blood pressure is the leading global cause of early death, accounting for nearly 10 million deaths in 2015, of which 4.9 million were caused by ischemic heart disease and 3.5 million, by stroke. Nocturnal blood pressure is a better predictor of cardiovascular events than diurnal blood pressure. According to the results of the Hygia study, administering medication at night could be a protective factor for cardiovascular events.

Based on these data, researchers developed prospective, randomized study TIME. Its objective was to show whether administering antihypertensive medication during the afternoon could improve the rates of cardiovascular events compared with morning medication.

Patients taking at least one antihypertensive drug were randomized 1:1 to drug administration in the morning or in the evening. The primary endpoint (PEP) was a composite of hospitalization for nonfatal acute myocardial infarction, nonfatal stroke, or vascular death.

Leia também: TAVI em bicúspides: os resultados são os mesmos em homens e mulheres?

The study included 21,104 patients with a mean age of 65 years; 58% of them were men, and the mean follow-up was 5.2 years. The PEP was observed in 3.4% of those who took the medication in the morning vs. 3.7% of those who took it in the afternoon (hazard ratio: 0.95; 95% confidence interval: 0.83-1.10; p = 0.53). These results did not vary between the different subgroups analyzed.

Conclusion

This study, with a very large cohort of patients, showed no changes in the occurrence of acute myocardial infarction, stroke, or vascular death based on the administration of antihypertensive treatments at different times of the day.

TIME STUDY ESC 2022
Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Membro do Conselho Editorial da SOLACI.org.

Fonte: MacDonald TM. TIME – the Treatment in Morning versus Evening study. Presentado en el Congreso Europeo de Cardiología ESC 2022. Agosto 26, 2022. Barcelona, España.


Subscreva-se a nossa newsletter semanal

Receba resumos com os últimos artigos científicos

Previous article
Next article

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

KISS Trial: provisional stenting in non-left main coronary bifurcations — is less more?

Coronary bifurcation angioplasty remains one of the most frequent and technically challenging scenarios in interventional cardiology. Between 15% and 20% of coronary procedures involve...

Complex radial access: a four-step protocol to overcome loops and tortuosity

Radial access is currently the preferred strategy for coronary angiography and percutaneous coronary interventions due to its lower rates of bleeding and vascular complications...

Percutaneous closure of paravalvular leaks in high-risk patients: clinical outcomes and the impact of residual leak

Paravalvular leak (PVL) is a relatively frequent complication following valve replacement (overall incidence 5–18%; 2–10% in the aortic position and 7–17% in the mitral...